Letolizumab, CAS 1450981-87-9

Product Description: Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time[1][2][3].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Karnell JL, et al. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev. 2019 Feb 15;141:92-103. /[2]Kim SC, et al. Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection. Am J Transplant. 2017 May;17(5):1182-1192./[3]Spicer P, et al. Costimulatory pathway targets for autoimmune and inflammatory conditions: clinical successes, failures, and hope for the future. Expert Opin Investig Drugs. 2019 Feb;28(2):99-106.

CAS Number: 1450981-87-9

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: TNF Receptor

• Artikelnummer: MEXHY-P99701-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99701-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated